Edition:
United Kingdom

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

7.50USD
21 Feb 2018
Change (% chg)

$0.40 (+5.63%)
Prev Close
$7.10
Open
$7.15
Day's High
$7.50
Day's Low
$7.10
Volume
19,572
Avg. Vol
22,769
52-wk High
$11.90
52-wk Low
$3.80

Chart for

About

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $136.71
Shares Outstanding(Mil.): 18.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Dry Eye Disease Phase 2B Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN DRY EYE DISEASE PHASE 2B CLINICAL TRIAL Source text for Eikon: Further company coverage:

30 Jan 2018

BRIEF-Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data

* ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING Source text for Eikon: Further company coverage:

29 Nov 2017

BRIEF-Aldeyra Therapeutics reports Q3 loss per share of $0.32

* Aldeyra Therapeutics announces third quarter 2017 financial results

09 Nov 2017

BRIEF-Aldeyra ‍announcesd new data for ADX-102 from Phase 2 clinical trials

* Aldeyra - ‍announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis​

10 Oct 2017

BRIEF-Perceptive Advisors buys 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19

* Perceptive Advisors Llc reports purchase of 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19 at $7.25 per share - SEC filing

21 Sep 2017

BRIEF-Aldeyra Therapeutics posts pricing of public offering of common stock

* Aldeyra Therapeutics Inc announces pricing of public offering of common stock

19 Sep 2017

BRIEF-Aldeyra Therapeutics announces proposed public offering of common stock

* Aldeyra Therapeutics Inc announces proposed public offering of common stock

18 Sep 2017

BRIEF-Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial

* Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial Source text for Eikon: Further company coverage:

12 Sep 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $129.91 -0.96
Novartis AG (NOVN.S) CHF80.20 -0.26
Pfizer Inc. (PFE.N) $35.76 -0.25
AbbVie Inc (ABBV.N) $117.91 -0.07
Amgen, Inc. (AMGN.OQ) $182.43 -0.55
Bristol-Myers Squibb Co (BMY.N) $66.53 -0.82
Bristol-Myers Squibb Co (BMYMP.PK) $1,042.55 --
UCB SA (UCB.BR) €65.90 -0.66

Earnings vs. Estimates